alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 522.914 Fenprostalene. ( a ) *Specifications.* ( 1 ) Each milliliter of solution contains 0.5 milligram (mg) fenprostalene.
( 2 ) Each milliliter of solution contains 0.25 mg fenprostalene.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter for use of product described in paragraph (a)(1) as in paragraph (e)(1) of this section; and for use of product described in paragraph (a)(2) as in paragraph (e)(2) of this section.
( c ) *Related tolerances.* See § 556.277 of this chapter.
( d ) *Special considerations.* Labeling shall bear the following statements: Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. It is readily absorbed through the skin and may cause abortion and/or bronchiospasms. Accidental spillage on the skin should be washed off immediately with soap and water.
( e ) *Conditions of use* — ( 1 ) *Cattle* — ( i ) *Indications for use and amount.* ( A ) For feedlot heifers to induce abortion when pregnant 150 days or less, administer 1 mg (2 milliliter (mL)) subcutaneously.
( B ) For beef or nonlactating dairy cattle for estrus synchronization, administer a single or two 1-mg (2-mL) doses subcutaneously, 11 to 13 days apart.
( ii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Swine* — ( i ) *Amount.* Administer a single injection of 0.25 mg (1 mL) subcutaneously.
( ii ) *Indications for use.* For the induction of parturition in sows and gilts pregnant at least 112 days.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16188, Mar. 25, 2014]
# C_2017053EN.01002901.xml

| 20.2.2017 | EN | Official Journal of the European Union | C 53/29 |
| --- | --- | --- | --- |

20.2.2017

EN

Official Journal of the European Union

C 53/29

---

Order of the General Court of 16 December 2016 — Ica Foods v EUIPO — San Lucio (GROK)

(Case T-774/14) (1)

1

((EU trade mark - Invalidity proceedings - Withdrawal of the application for registration - No need to adjudicate))

(2017/C 053/35)

Language of the case: Italian

Parties

Parties

Applicant: Ica Foods SpA (Pomezia, Italy) (represented by: A. Nespega, lawyer)

Applicant:

Defendant: European Union Intellectual Property Office (represented by: L. Rampini, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: San Lucio Srl (San Gervasio Bresciano, Italy) (represented by: F. Sangiacomo, lawyer)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court:

Re:

Re:

Action brought against the decision of the Second Board of Appeal of EUIPO of 9 September 2014 (Case R 1815/2013-2), relating to invalidity proceedings between San Lucio Srl and Ica Foods SpA.

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to rule on the action. |
| --- | --- |

1.

There is no longer any need to rule on the action.

| 2. | Ica Foods SpA and San Lucio Srl shall bear their own costs and shall each pay half of the costs incurred by the European Union Intellectual Property Office (EUIPO). |
| --- | --- |

2.

Ica Foods SpA and San Lucio Srl shall bear their own costs and shall each pay half of the costs incurred by the European Union Intellectual Property Office (EUIPO).

---

(1)  OJ C 26, 26.1.2015.

1

---
<PAGE>

                                                                    EXHIBIT 32.2

                                  CERTIFICATION
                           PURSUANT TO 18 U.S.C. 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      I, Donald M. Muir, Chief Financial Officer of Evergreen Solar, Inc.,
certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Evergreen
Solar, Inc. for the fiscal year ended December 31, 2005 fully complies with the
requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934
and that information contained in such Annual Report on Form 10-K fairly
presents, in all material respects, the financial condition and results of
operations of Evergreen Solar, Inc.

Date: March 16, 2006                          /s/ Donald M. Muir
                              --------------------------------------------------
                                                Donald M. Muir
                                  Vice President and Chief Financial Officer

      A signed original of this written statement required by Section 906 has
been provided to Evergreen Solar, Inc. and will be retained by Evergreen Solar,
Inc. and furnished to the Securities and Exchange Commission or its staff upon
request.
#### § 822.19 What kinds of decisions may you make?

| If your plan: | Then we will send you: | And you must: |
| --- | --- | --- |
| (a) Should result in the collection of useful data that will address the postmarket surveillance question | An approval order, identifying any specific requirements related to your postmarket surveillance | Conduct postmarket surveillance of your device in accordance with the approved plan |
| (b) Should result in the collection of useful data that will address the postmarket surveillance question after specific revisions are made or specific information is provided | An approvable letter identifying the specific revisions or information that must be submitted before your plan can be approved | Revise your postmarket surveillance submission to address the concerns in the approvable letter and submit it to us within the specified timeframe. We will determine the timeframe case-by-case, based on the types of revisions or information that you must submit |
| (c) Does not meet the requirements specified in this part | A letter disapproving your plan and identifying the reasons for disapproval | Revise your postmarket surveillance submission and submit it to us within the specified timeframe. We will determine the timeframe case-by-case, based on the types of revisions or information that you must submit |
| (d) Is not likely to result in the collection of useful data that will address the postmarket surveillance question | A letter disapproving your plan and identifying the reasons for disapproval | Revise your postmarket surveillance submission and submit it to us within the specified timeframe. We will determine the timeframe case-by-case, based on the types of revisions or information that you must submit |
# C_2018005EN.01002501.xml

| 8.1.2018 | EN | Official Journal of the European Union | C 5/25 |
| --- | --- | --- | --- |

8.1.2018

EN

Official Journal of the European Union

C 5/25

---

Judgment of the General Court of 16 November 2017 — USFSPEI v Parliament and Council

(Case T-75/14) (1)

1

((Action for annulment - Time limit for bringing proceedings - Inadmissibility - Non-contractual liability - Reform of the Staff Regulations and of the CEOS - Regulation (EU, Euratom) No 1023/2013 - Irregularities during the procedure for the adoption of the acts - Failure to consult the Staff Regulations Committee and the staff unions - Sufficiently serious breach of a rule of law intended to confer rights on individuals))

(2018/C 005/33)

Language of the case: French

Parties

Parties

Applicant: Union syndicale fédérale de services publics européens et internationaux (USFSPEI) (Brussels, Belgium) (represented initially by: J.-N. Louis and D. de Abreu Caldas and subsequently by: J.-N. Louis, lawyers)

Applicant:

Defendants: European Parliament (represented by: A. Troupiotis and E. Taneva, acting as Agents) and Council of the European Union (represented initially by: M. Bauer and A. Bisch, and subsequently by: M. Bauer and M. Veiga, acting as Agents)

Defendants:

Intervener in support of the defendants: European Commission (represented initially by: G. Gattinara and J. Currall, and subsequently by: G. Gattinara and G. Berscheid, acting as Agents)

Intervener in support of the defendants:

Re:

Re:

Firstly, application on the basis of Article 263 TFEU seeking the annulment of Article 1(27), (32), (46), (61), (64)(b), (65)(b) and (67)(d) of Regulation (EU, Euratom) No 1023/2013 of the European Parliament and of the Council of 22 October 2013 amending the Staff Regulations of Officials of the European Union and the Conditions of Employment of Other Servants of the European Union (OJ 2013 L 287, p. 15) and, secondly, application on the basis of Article 268 TFEU seeking compensation for the loss which the applicant allegedly suffered following the adoption of Regulation No 1023/2013 in breach of the agreement on the 2004 Reform, of Articles 12 and 27 of the Charter of Fundamental Rights of the European Union, of Article 10 of the Staff Regulations and of the consultation procedure provided for in the Council Decision of 23 June 1981.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Union syndicale fédérale de services publics européens et internationaux (USFSPEI) to bear its own costs and to pay the costs incurred by the European Parliament and the Council of the European Union; |
| --- | --- |

2.

Orders Union syndicale fédérale de services publics européens et internationaux (USFSPEI) to bear its own costs and to pay the costs incurred by the European Parliament and the Council of the European Union;

| 3. | Orders the European Commission to bear its own costs. |
| --- | --- |

3.

Orders the European Commission to bear its own costs.

---

(1)  OJ C 194, 24.6.2014.

1

---
Poly (sodium itaconate co butenoate)

Structure not shown
###### Editorial Note on Part 862

#### Editorial Note:

Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

#### § 862.2 Regulation of calibrators.

Many devices classified in this part are intended to be used with a calibrator. A calibrator has a reference value assigned to it which serves as the basis by which test results of patients are derived or calculated. The calibrator for a device may be (a) manufactured and distributed separately from the device with which it is intended to be used, (b) manufactured and distributed as one of several device components, such as in a kit of reagents, or (c) built-in as an integral part of the device. Because of the central role that a calibrator plays in the measurement process and the critical effect calibrators have on accuracy of test results, elsewhere in this part, all three of these types of calibrators (§§ 862.1150 and 862.3200 of this part) are classified into class II, notwithstanding the classification of the device with which it is intended to be used. Thus, a device and its calibrator may have different classifications, even if the calibrator is built into the device.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-29-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               DEC-29-1996
<CASH>                                           1,175
<SECURITIES>                                         0
<RECEIVABLES>                                   56,469
<ALLOWANCES>                                         0
<INVENTORY>                                     97,975
<CURRENT-ASSETS>                               184,562
<PP&E>                                       1,240,119
<DEPRECIATION>                                 561,965
<TOTAL-ASSETS>                                 945,599
<CURRENT-LIABILITIES>                          148,293
<BONDS>                                        447,229
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       129,058
<OTHER-SE>                                       1,905
<TOTAL-LIABILITY-AND-EQUITY>                   945,599
<SALES>                                        925,376
<TOTAL-REVENUES>                               925,376
<CGS>                                          850,419
<TOTAL-COSTS>                                  850,419
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                   465
<INTEREST-EXPENSE>                              49,920
<INCOME-PRETAX>                               (26,623)
<INCOME-TAX>                                  (10,087)
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (16,536)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0


</TABLE>
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1555 Phenylalanine test system. ( a ) *Identification.* A phenylalanine test system is a device intended to measure free phenylalanine (an amino acid) in serum, plasma, and urine. Measurements of phenylalanine are used in the diagnosis and treatment of congenital phenylketonuria which, if untreated, may cause mental retardation.
( b ) *Classification.* Class II.
UN PUBLISHED
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 09 - 7549

MARCO BATES , Petitioner

- Appellant ,

v. MCKI THER BODISON, Warden of Lieber Correctional Institution ,

Respondent

- Appellee
.

Appeal from the United States D istrict Court for the District of South Carolina , at Rock Hill
. Henry M. Herlong, Jr. , Senior District Judge. ( 0:08

- cv - 02273

- HMH )

Submitted : December 31, 2009 Decided: March 1 , 2010

Before MOTZ, KING , and AGEE , Circuit Judges.

Dismissed by un p ublished per curiam opinion
. Marco Bates, Appellant Pro Se. William Edgar Salter, III, Assistant Attorney General, Donald John Zelenka, Deputy Assistant Attorney General, Columbia, South Carolina, for Appellee.
Unpublished opinions are not binding pr ecedent in this circuit.2

PER CURIAM:

Marco Bates seeks to appeal the district court ’ s order accepting the recommendation of the magistrate judge and denying relief on his 28 U.S.C. § 2254 (2006) petition. The order is not appealable unless a circuit jus tice or judge issues a certificate of appealability. See 28 U.S.C. § 2253(c)(1) (2006) . A certificate of appealability will not issue absent “ a substantial showing of the denial of a constitutional right. ” 28 U.S.C. § 2253(c)(2) (2006) . A prisoner sati sfies this standard by demonstrating that reasonable jurists would find that any assessment of the constitutional claims by the district court is debatable or wrong and that any dispositive procedural ruling by the district court is likewise debatable. Se e Miller

El v. Cockrell , 537 U.S. 322, 336

- 38 (2003); Slack v. McDaniel , 529 U.S. 473, 484 (2000); Rose v. Lee , 252 F.3d 676, 683

- 84 (4th Cir. 2001). We have independently reviewed the record and conclude that Bates has not made the requisite showing.
Ac cordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional
process. DISMISSE D
### Surface water supply of the United States, 1961-65, Part 9. Colorado River basin, Volume 3. Lower Colorado River basin

By: Water Resources Division, U.S. Geological Survey

                            https://doi.org/10.3133/wsp1926

#### Links

-                                                                                                                             Document:                                                                                                                                                                                                                                                  **Report**                                                                                                     (pdf)                                                                                                                                     
- Plate:  **Plate 1**                            (pdf)
- NGMDB Index Page:  **National Geologic Map Database Index Page**                            (html)
- Download citation as:  RIS                         |                         Dublin                            Core

#### Abstract

No abstract available.

#### Study Area

Part or all of this report is presented in Portable Document Format                        (PDF). For best results viewing and printing PDF documents, it is recommended that you download                        the documents to your computer and open them with Adobe Reader. PDF documents opened from your                        browser may not display or print as intended. Download the latest version of Adobe Reader, free of charge. More information                        about viewing, downloading, and printing report files can be found at the common download problems FAQ.
<PAGE>   1
THE LOEWEN GROUP INC.
--------------------------------------------------------------------------------
(NYSE, TSE, ME: LWN)
          NEWS


Contact:
Thomas C. Franco
Broadgate Consultants, Inc.
Tel: (212) 232-2222


                  LOEWEN GROUP ANNOUNCES MANAGEMENT REALIGNMENT

          -------------------------------------------------------------

VANCOUVER, BC, November 20, 1998 -- The Loewen Group Inc. (NYSE, TSE, ME: LWN)
today announced that its Board of Directors has approved a realignment of the
Company's senior management team. In the realignment, Paul Wagler assumes the
position of Executive Vice-President Operations and Chief Operating Officer.
Michael Weedon assumes the position of Executive Vice-President Administration,
Accounting and Control and Chief Administrative Officer. Andrew Scott assumes
the position of Senior Vice-President Finance and Corporate Development and
Acting Chief Financial Officer. In addition Tim Hogenkamp assumes the position
of Executive Vice-President Corporate Affairs. Each of these officers reports to
Robert B. Lundgren, President, Chief Executive Officer and Co-Chairman of the
Company.

The Loewen Group Inc. is the second largest funeral home and cemetery operator
in North America. The Company employs approximately 16,000 people and owns or
operates more than 1,100 funeral homes and over 500 cemeteries across the United
States, Canada and the United Kingdom. Over 90 percent of the Company's revenue
is derived from the United States.

The Loewen Group's website is located at http://www.loewengroup.com
#### People of the State of Illinois, Plaintiff-Appellee, v. Curtis Haley, Defendant-Appellant.

Gen. No. 51,262. (Abstract of Decision.)

First District, Second Division.

April 1, 1969.

Rehearing denied April 22, 1969.

Gerald W. Getty, Public Defender of Cook County, of Chicago (Marshall J. Hartman and James J. Doherty, Assistant Public Defenders, of counsel), for appellant; Edward V. Hanrahan, State’s Attorney of Cook County, of Chicago (Eljner C. Kissane and Michael Stevenson, Assistant State’s Attorneys, of counsel), for appellee.

Opinion by

JUSTICE McCORMICK.

Not to be published in full.
Exhibit 10.8


 





AMENDMENT


TO


STOCK OPTION AGREEMENT


 


This Amendment to Stock
Option Agreement (this “Amendment”) is entered into by and between JOSEPH DOWLING, an individual (“Executive”),
and CV SCIENCES, INC., a Delaware corporation (the “Company”) as of March 16, 2017 (the “Effective Date”),
with reference to the following facts:


 


RECITALS


 


A.               
On July 6, 2016 Executive and the Company entered into that certain Non-Qualified Stock Option Agreement (the “Agreement”),
a copy of which is attached hereto and incorporated herein by this reference as Exhibit A;


 


B.                
Each of the parties hereto desires to enter into this Amendment to amend the Agreement as set forth herein.


 


AGREEMENT


 


NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:


 


1.                 
Vesting Agreement. Subparagraphs (a)(i) through (iii) are superseded and replaced as follows, as related to the
Options not yet vested as of the Effective Date:


 


(i)                
“Thirty-four percent (34%) when the Company has final meeting minutes from a pre-investigational new drug application
(“IND”) meeting as authorized by the FDA for a drug development program utilizing CBD as the active pharmaceutical
ingredient;


 


(ii)             
Thirty-three percent (33%) when the Company is granted an IND; and


 


(iii)           
Thirty-three percent (33%) when the Company commences its first human dosing under the IND.”


 


2.                 
Conflict. If there is a conflict between the terms and conditions of this Amendment and the terms and conditions
of the Agreement, the terms and conditions of this Amendment shall control. Except as modified by this Amendment, the terms and
conditions of the Agreement shall remain in full force and effect.


 


 


[signature page follows]


 


 


 


 


 






    	 	1	 



     

    

 


IN WITNESS WHEREOF,
the undersigned have executed this Amendment as of the Effective Date.


 


 


CV SCIENCES, INC.


 


 


By: /s/ James McNulty                      


Name: James McNulty


Its: Chairman, Compensation Committee


 


 


 


/s/ Joseph Dowling                         


Joseph Dowling


 


 


 


 


 


 


 


 


 


 


 


 


 


 






    	 	2	 



     

    






Exhibit A


 


NON-QUALIFIED STOCK OPTION AGREEMENT


 


[see attached]


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 






    	 	3
UNPUBLISHED

UNITED STATES COURT OF APPEALS 

FOR THE FOURTH CIRCUIT 

No. 11-1249

DEREK N. JARVIS, 

 Plaintiff - Appellant, 

 v. 

DEBORAH K. CHASANOW, Chief Judge, US District Court for the 

District of Maryland; CHARLES B. DAY, Magistrate Judge, US 

District Court for the District of Maryland; PETER J. 

MESSITTE, Judge, US District Court for the District of 

Maryland; UNITED STATES DISTRICT COURT CLERK’S OFFICE; 

TRAXLER, Chief Judge, US Court of Appeals for the Fourth 

Circuit; WILKINSON, Circuit Judge, US Court of Appeals for 

the Fourth Circuit; NIEMEYER, Circuit Judge, US Court of 

Appeals for the Fourth Circuit; AGEE, Circuit Judge, US 

Court of Appeals for the Fourth Circuit, 

 Defendants - Appellees. 

Appeal from the United States District Court for the District of 

Maryland, at Greenbelt. Alexander Williams, Jr., District 

Judge. (8:11-cv-00627-AW) 

Submitted: September 29, 2011 Decided: October 4, 2011 

Before KING, GREGORY, and DUNCAN, Circuit Judges. 

Affirmed by unpublished per curiam opinion. 

Derek N. Jarvis, Appellant Pro Se. 

Unpublished opinions are not binding precedent in this circuit. 

Certiorari dismissed, February 21, 2012
2

PER CURIAM:

Derek N. Jarvis appeals the district court’s order 

denying relief on his 42 U.S.C. § 1983 (2006) complaint. We 

have reviewed the record and find no reversible error. 

Accordingly, we affirm for the reasons stated by the district 

court. Jarvis v. Chasanow, No. 8:11-cv-00627-AW (D. Md. Mar. 

15, 2011); see Briscoe v. LaHue, 460 U.S. 325, 335 (1983) 

(noting that quasi-judicial immunity accorded to individuals who 

play integral part in judicial process); Johnson v. Turner, 125 

F.3d 324, 332 (6th Cir. 1997) (finding clerk’s office employees, 

acting as a judge’s designee, are entitled to quasi-judicial 

immunity). We dispense with oral argument because the facts and 

legal contentions are adequately presented in the materials 

before the court and argument would not aid the decisional 

process.

AFFIRMED